Follow the 휴젤 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 휴젤 has recorded 41 insider filings. Market capitalisation: €2,825.1bn. The latest transaction was reported on 2 July 2026 (Sale). Among the most active insiders: 아프로디테애퀴지션홀딩스엘엘씨. The full history is accessible without an account.
39
Insider Decl.
n/a
Thresholds
€11,681
6 ops.
Buy Volume
n/a
18 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 휴젤 Strong Buy (bullish), based on 16 analysts. Average price target: ₩360,563.
23Σ signal
Buys €11,681n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 3,098 of 28,065 companies
72.8
score / 100
Value
57
Quality
89
FCF yld4.3%
Earn yld5.0%
EV/EBITDA13.1x
ROE16%
Gross mgn78%
Net mgn33%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
휴젤 is a South Korean company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on the development and commercialization of pharmaceutical products and medical devices.